spacer
home > ebr > winter 2018 > regional requirements
PUBLICATIONS
European Biopharmaceutical Review

Regional Requirements

Globalisation has affected the life sciences and pharmaceutical industries just as much as it has other sectors, and a growing push to standardise submission formats has opened market opportunities for many life sciences companies. The common technical document (CTD) has already become the de facto standard in many regions as more and more countries respond to the ICH’s mission of greater harmonisation around the “interpretation and application of technical guidelines and requirements for pharmaceutical product registration” (1).

Regional Regulatory Climate

Today, most countries – either directly or through regional agencies – are members of the ICH or observe its guidelines. Through ongoing consultations between ICH and regulatory agencies, most regions of the world either have adopted – or are working towards meeting – the ICH guidelines centred on the areas of quality, safety, efficacy and multidisciplinary regulatory issues.

Even though most countries and regions are still paper-based, the push towards electronic submission is growing, and more countries are adopting or at least exploring electronic CTD initiatives. However, regional differences remain, even where strong alliances and a structured approach to regulatory submissions exist.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kimty Bui-Van is head of regulatory and pharma services practice at ProductLife Group, where she is responsible for the coordination of all regulatory affairs activities undertaken on behalf of clients. She draws on nearly 20 years of experience in regulatory affairs, both within the industry and as a consultant, to guide clients through all aspects of regulatory affairs, including initial submissions, variations, renewals and product lifecycle management. Kimty has been instrumental in establishing a transformative approach to managing affiliate regulatory and pharmacovigilance activities globally on behalf of clients. 
spacer
Kimty Bui-Van
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

Vaccine Manufacturing

23-25 April 2018, RAI, Amsterdam

Changing the shape of vaccine development, manufacturing and delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement